Background
==========

Isoniazid (INH) is one of the most effective and specific agents for the treatment of the disease caused by *Mycobacterium tuberculosis*(MTB). It is a cornerstone of the modern short-course chemotherapy for tuberculosis, and also widely used to treat the latent MTB infection (LTBI) to prevent the active disease and the subsequent TB transmission.

However, recent increases both in INH-resistant and multidrug-resistant (MDR) tuberculosis have been jeopardizing the efforts of global TB control through the implementation of the Directly Observed Treatment, Short course (DOTS) \[[@B1],[@B2]\]. In China, DOTS program has been adopted since early 1990s, but the increased prevalence of drug resistant TB has become a significant challenge for TB control in last ten years. The prevalence of MDR-TB and INH resistant TB was estimated as 8.3% and 41.2% respectively among all cases in China, which were both high compared to the global estimates of 4.8% and 13.3% \[[@B3]\].

The development of INH resistance is a common first step in the evolution to MDR \[[@B4]\]. Thus, there has been considerable interest in both identifying the molecular basis of INH resistance and understanding the transmission pattern of the INH resistant MTB strain.

Resistance to INH is mediated by mutations in different genes in MTB, with *katG*\[[@B5]\] and *inhA*\[[@B6]\] being the most common. The mutation in the *katG*gene is a major mechanism of INH resistance in MTB \[[@B7]-[@B9]\]. The most common mutation is the Ser315Thr substitution in the *katG*gene, which is present in approximately 50-90% of all INH-resistant isolates and is associated with relatively high-level resistance to INH \[[@B9]\]. The mutation in *inhA*or its promoter region can cause 21-24% of INH resistance, with the promoter mutation (mainly in the *inhA*-15 position) being more common than the mutation in the structural gene \[[@B8]\]. A study of INH resistance in MTB has reported that a certain INH resistant strain with the *katG*315Thr mutation had a strong association with the development of MDR, and the successful transmission of MDR MTB as well \[[@B10]\].

Based on the above knowledge and findings, we hypothesized that specific INH resistant MTB strains could perpetuate the epidemic of MDR-TB in high TB burden countries like China.

Here we presented an in-depth study to determine the molecular basis of INH-resistant MTB and the transmission pattern of INH resistant MTB circulating in two rural counties of eastern China. We applied direct DNA sequencing on hotspots of *katG*and *inhA*genes/promoters as well as the IS*6110*restriction fragment length polymorphism (RFLP) genotyping technique to analyze the level of clustering or recent transmission of INH-resistant MTB. Combined with epidemiological evidence, the molecular information obtained from this study could give us a better understanding of the possible mechanism behind the high prevalence of MDR-TB in rural China.

Methods
=======

Study population
----------------

The epidemiological methods and study population of this study were described previously \[[@B11]\]. It is a population-based cross-sectional study carried out in two rural counties in eastern China, i.e., Deqing County in Zhejiang Province and Guanyun County in Jiangsu Province. All TB patients notified in the County TB dispensaries within one year were enrolled in the study (Deqing, from April 1, 2004 to March 31, 2005; Guanyun, from June 1, 2004 to May 31, 2005).

Drug susceptibility test
------------------------

All MTB isolates were tested for drug susceptibility using the proportion method on egg-based LJ medium \[[@B12]\]. The critical drug concentration were 0.2 μg/ml for isoniazid (INH), 40 μg/ml for rifampicin (RIF), 4 μg/ml for streptomycin (STR) and 2 μg/ml for ethambutol (EMB). Resistance was defined as the growth of more than 1% colonies compared to the drug free control. MDR was defined as drug resistance to at least INH and RIF. Poly drug-resistance was defined as resistance to more than one of the tested anti-TB drugs but not to both INH and RIF simultaneously.

DNA sequencing
--------------

All isolates available were investigated for the presence of the hotspot mutations related to drug resistance by direct DNA sequencing. The hotspot genes included *rpoB*, *katG*genes and the *inhA*promoter region, corresponding to the drug resistance to RIF and INH respectively. The Primers pairs were CCCATGGCCGCGGCGGTCGACATT and CGCCGTCCTTGGCGGTGTATTGCC for *katG*gene (GeneBank: [X68081](X68081)), and CCTCGCTGCCCAGAAAGGGA and ATCCCCCGGTTTCCTCCGGT for *inhA*promoter region (GeneBank: [U41388](U41388)), and GGGAGCGGATGACCACCCA and GCGGTACGGCGTTTCGATGAAC for *rpoB*gene (GeneBank: [L27989](L27989)). Mutations in these genes were determined by amplification of the corresponding hotspot DNA region by PCR followed by direct DNA sequencing with ABI 3770 DNA sequencer (Applied Biosystems, Inc., Foster City, CA, USA). The new alleles were confirmed by further PCR and re-sequencing from the original DNA. Sequencing data was independently analyzed by two biologists for quality control purposes.

IS*6110*-RFLP genotyping
------------------------

IS*6110*RFLP was done on the INH resistant isolates according to the standard protocol of van Embden et al, with data analyzed by the Gel Compar software (version 4.6, Applied Maths, Belgium) \[[@B13]\]. A cluster is defined as two patient MTB isolates harboring the identical IS*6110*RFLP pattern. Unique strains denote unparallelness of the IS*6110*RFLP profiles in the study collection. Typically, clustered strains indicate recent transmission while unique strains indicate reactive disease from a remote infection.

Spoligotyping
-------------

Spoligotyping was carried out by using the commercial kit from Isogen Bioscience BV (Maarssen, The Netherlands) \[[@B10]\]. The INH resistant strain clades were determined by comparison of the spoligotyping pattern with the SpolDB3 database \[[@B14]\] in the SpotClust program (available in <http://cgi2.cs.rpi.edu/~bennek/SPOTCLUST.html>) and assigned with the corresponding spoligotype international type (SIT). The Beijing family MTB was defined as the strain that hybridized only to the last nine spacer oligonucleotides (spacers 35 to 43).

Statistics analysis
-------------------

SPSS software (SPSS Inc., Chicago, IL, USA) was utilized for the statistics analysis. Clinical and bacteriological characteristics were compared between *katG*315Thr alleles and other INH resistant isolates using the Mantel-Haenszel chi-square test. Binary logistic regression model was used for univariate and multivariate analysis to qualify and quantify the difference in clustering proportion between groups of subjects with different socio-demographic and clinical characteristics. The adjusted Odds Ratio (OR) and 95% confidence interval (CI) were calculated by adjusting for the possible confounders (age, county and sex).

The study was approved by the Institutional Review Board of Fudan School of Public Health. Written informed consent was obtained from all the participants.

Results
=======

In total, drug resistance profile and baseline information were successfully obtained from 399 pulmonary TB patients, 182 in Deqing and 217 in Guanyun during the study period. Of the 399 MTB isolates from these patients, 251 (62.9%) were resistant to at least one of 1^st^line anti-TB drugs. Resistance to INH was the most common form of drug resistance (140/251) with a majority of cases mono-resistant to INH (55/140). Resistance to RIF was observed in 65 isolates, only 2 of which were mono-resistant. A total of 58 isolates were resistant to INH and RIF simultaneously. The details of the resistance have been reported previously \[[@B11]\].

DNA samples were successfully extracted from 131 of the 140 INH resistant isolates. Of the 131 isolates, 80 were from patients who were previously diagnosed with TB and 51 were from the patients newly diagnosed. Regarding the drug resistance profile, apart from the 55 INH mono-resistant isolates, 53 were also resistant to RIF and referred to as MDR-TB; 23 were poly-resistant (INH + STR and/or EMB) (Table [1](#T1){ref-type="table"}).

###### 

Drug susceptibility profile of INH resistant MTB isolates from the study sites

  ----------------------------------------------------------------------------------
  Drug resistance\   Total *n*= 131   No. of isolates from patients with:   
  profile                                                                   
  ------------------ ---------------- ------------------------------------- --------
   **H**             **55**           **30**                                **25**

  **MDR-TB**         **53**           **33**                                **20**

   HR                32               21                                    11

   HRS               12               6                                     6

   HRE               5                3                                     2

   HRSE              4                3                                     1

  **PDR-TB**         **23**           **17**                                **6**

   HS                13               9                                     4

   HE                2                1                                     1

   HSE               8                7                                     1
  ----------------------------------------------------------------------------------

NOTE: H, isoniazid; R, rifampicin; S, streptomycin; E, ethambutol;

MDR-TB, multidrug-resistant tuberculosis; PDR-TB, polydrug-resistant tuberculosis.

DNA sequencing demonstrated that 107 of 131 INH resistant isolates had mutations either in the *katG*gene or in the *inhA*promoter (Table [2](#T2){ref-type="table"}): 61.8% (81/131) of the isolates had a mutation in the position 315 of *katG*, of which 56.5% (74/131) INH resistant isolates contained the *katG*Ser315Thr nucleotide substitution. *katG*315Arg and *katG*315Asn mutations were detected in 3 and 4 isolates respectively. In addition, 28 of 131 INH resistant isolates (21.4%) presented the mutation in the *inhA*promoter region, all of which possessed the *inhA*-15 C→T nucleotide substitution. Two INH resistant isolates shared the mutation in *katG*and *inhA*gene simultaneously: one with *katG*315Thr and *inhA*-15T mutations and the other with *katG*315Arg and *inhA*-15T mutations. No nucleotide substitutions were identified in 220 INH sensitive isolates either at the *katG*315 position or the *inhA*-15 position. The frequency of the *katG*315Thr mutation was significantly higher in MDR-TB compared to the other drug resistant form of MTB isolates (67.9%.vs.48.7%; χ^2^, 4.736; *p*, 0.030), while *inhA*-15T mutations did not differ significantly between these two major drug susceptibility groups (20.8%.vs.21.8%; χ^2^, 0.020; *p*, 0.887).

###### 

Genetic mutations and their frequencies related to INH resistance in MTB isolates from the study sites

  Drug resistance   Total   *katG*315Ser → \*   *inhA*-15C→ \*   *katG*+   wt       
  ----------------- ------- ------------------- ---------------- --------- ---- --- ----
   H                55      2                   1                28        12   0   12
  **MDR-TB**                                                                        
   HR               32      0                   1                19        6    1   5
   HRS              12      0                   0                9         2    1   0
   HRE              5       0                   0                5         0    0   0
   HRSE             4       0                   1                2         1    0   0
  **PDR-TB**                                                                        
   HS               13      0                   0                5         3    0   5
   HE               2       0                   0                0         1    0   1
   HSE              8       0                   1                5         1    0   1

NOTE: H, isoniazid; R, rifampicin; S, streptomycin; E, ethambutol.

MDR-TB, multidrug-resistant tuberculosis; PDR-TB, polydrug-resistant tuberculosis.

\*: No. of isolates with mutations in single gene.

§: No. of isolates with mutations in multiple genes. Two INH resistant isolates shared the mutation in *katG*and *inhA*gene simultaneously: one with *katG*315Thr and *inhA*-15T mutations and the other with *katG*315Arg and *inhA*-15T mutation.

The resistance to RIF was due to mutations in the *rpoB*gene in 49 of 53 MDR-TB isolates. A single-nucleotide substitution in position 516, 526 and 531 accounted for 7.5%, 30.2% and 58.5% respectively of MDR-TB. The mutations in *rpoB*gene included 516Tyr (3/53), 516Val (2/53), 526Arg (4/53), 526Tyr (11/53) and 531Leu (31/53). Double-spot mutations were presented in two MDR isolates, one with 516Tyr/531Leu mutations and the other with 516Val/531Leu mutations. No *rpoB*mutations were observed in isolates susceptible to RIF.

MTB clades designations were available for 122 of 131 isolates, with the following distribution of the genotypic lineages (Table [3](#T3){ref-type="table"}): Beijing family (105/131 or 80.1%), Family 33 (8/131 or 6.1%), T lineage (7/131 or 5.3%), Haarlem (1/131 or 0.8%) and LAM (1/131 or 0.8%). Of the remaining 9 isolates, 6 had the spoligotyping pattern similar to T lineage, 1 similar to Family 33, 1 similar to Haarlem and 1 similar to LAM.

###### 

Spoligotyping pattern and frequency of the MTB isolates included

  Octal designation    Clade\*    Probability^§^   SIT    No. of isolates
  -------------------- ---------- ---------------- ------ -----------------
  0000 0000 0003 771   Beijing    0.99             1      105
  5777 7777 7760 771   T1         0.99             334    2
  7777 7777 7760 031   T1         0.99             239    1
  7777 7777 7760 771   T1         0.99             53     4
  7777 7736 7730 771   T1         0.79             new    1
  7777 2737 7730 771   T1         0.79             new    1
  7777 7777 7730 771   T1         0.79             2597   1
  7577 3737 7730 771   T1         0.79             new    1
  7736 3737 7730 771   T1         0.79             new    1
  7736 7777 7730 771   T1         0.79             new    1
  7777 7777 7146 741   Family33   0.99             new    1
  5777 7763 3566 731   Family33   0.99             new    1
  7767 6767 1146 771   family33   0.99             new    1
  7777 7377 7731 771   family33   0.99             new    2
  7777 7777 1146 771   family33   0.99             new    1
  7777 3717 7733 571   Family33   0.99             new    1
  7777 3771 7731 761   Family33   0.99             new    1
  7777 7777 7630 771   Family33   0.70             new    1
  7777 7777 6000 371   Haarlem1   0.98             1498   1
  5777 7777 7700 771   Haarlem3   0.77             new    1
  7777 7760 3560 731   LAM9       0.99             new    1
  6777 7760 7560 771   LAM1       0.51             1755   1

NOTE: SIT, spoligotype international type.

\*: Spotclust program-assigned clade.

§: Probability that the spoligotyping pattern belongs to the clade.

In the clustering analysis of INH resistant isolates specific to counties (Figure [1](#F1){ref-type="fig"}), IS*6110*RFLP identified all together 94 IS*6110*RFLP patterns, including 11 cluster patterns (27 isolates), 28 unique patterns/isolates in Deqing, 15 cluster patterns (36 isolates) and 40 unique patterns/isolates in Guanyun. The genotype and phenotype patterns of drug resistant TB were further investigated among the clustered isolates. Ten clusters (25 isolates) from Deqing and 12 clusters (32 isolates) from Guanyun contained isolates with different phenotype and/or genotype of drug resistance. In these clusters, INH resistant isolates with the *katG*315Thr mutation had the highest occurrence (51/57 or 89.5%). Additionally, 31 of 53 MDR-TB isolates (58.5%) were observed in 19 clusters, with all carrying the *katG*315Thr mutation as well as the mutations either in position 516, 526 or 531 of the *rpoB*gene. In these clusters containing MDR-TB isolates, 18 clusters had INH-mono resistant and/or polydrug-resistant TB isolates simultaneously.

![**The phenotypes and genotypes of INH resistant MTB isolates with cluster and unique pattern respectively in Deqing and Guanyun**. NOTE. DR, 1^st^line Drug resistance profile. \*: The circle contained the code for the cluster. §: Sequence of drugs was isoniazid, rifampicin, streptomycin, ethambutol; R, resistant; S, susceptible.](1471-2334-10-43-1){#F1}

Binary logistic regression was applied to analyze the \"clustering\" of INH resistant isolates in association with patients\' demographics, clinic profiles and the bacteriologic features (Table [4](#T4){ref-type="table"}). Smear-positive TB patients had a significantly higher proportion of clustered INH resistant MTB strain than smear-negative patients (54.9%.vs.36.7%; adjusted OR, 2.286; *p*, 0.032; 95%CI,1.075-4.863), as well as the previously diagnosed patients when compared to newly diagnosed patients (60.8%.vs.40.0%; adjusted OR, 2.159; *p*, 0.040; 95%CI,1.037-4.495). A significant higher proportion of MDR-TB isolates was clustered compared to INH mono resistant isolates (58.5%.vs.38.2%; adjusted OR, 2.384; *p*, 0.030; 95%CI, 1.089-5.220). Compared with the wild type (wt) isolates, the isolates with the *katG*315Thr mutation were more likely to be clustered (73.0%.vs.18.0%; adjusted OR, 12.70; *p*, 0.001; 95%CI, 6.357-14.80). The Beijing family isolates was mainly observed in clusters (56.2%.vs.15.4%; adjusted OR, 5.289; *p*, 0.001; 95%CI, 1.832-15.26). The INH resistant *inhA*-15T mutant isolates were more likely to be \"unique\" compared to those *inhA*-15 wild type isolates (14.3%.vs.57.3%; adjusted OR, 0.120; *p*, 0.001; 95CI%, 0.038-0.375).

###### 

Binary logistic regression analysis on the associations between demographical, clinical and bacteriological characteristics and clustering of INH resistant MTB isolates in the present study

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                     INH resistant isolates   unadjusted\   adjusted\   *p*     95%CI              
                                                                                         OR            OR\*                                   
  ------------------------------------------------------------- ------------------------ ------------- ----------- ------- ------- ---------- -------------
  **[Social-demographic and clinical characteristics:]{.ul}**                                                                                 

  Age (year)                                                    *18\~*                   34            12(35.3)    1                          

                                                                *30\~*                   65            34(52.3)    2.011                      

                                                                *60\~*                   32            17(53.1)    2.078                      

  Sex                                                           *Female*                 46            22(47.8)    1                          

                                                                *Male*                   85            41(48.2)    1.163                      

  County                                                        *Deqing*                 55            27(49.1)    1                          

                                                                *Guanyun*                76            36(47.4)    0.933                      

  BMI                                                           ≥*18.5*                  94            41(43.6)    1       1                  

  Index                                                         \<*18.5*                 37            22(59.5)    1.896   1.833   0.13       0.836-4.019

  Treatment                                                     *New*                    80            32(40.0)    1       1                  

  history                                                       *Previously*             51            31(60.8)    2.325   2.159   0.040^§^   1.037-4.495

  Sputum                                                        *negative*               49            18(36.7)    1       1                  

  smear                                                         *positive*               82            45(54.9)    2.095   2.286   0.032^§^   1.075-4.863

  Cavity                                                        *No*                     111           50(45.0)    1       1                  

                                                                *Yes*                    20            13(65.0)    2.266   2.423   0.091      0.868-6.761

  **[Bacteriological features:]{.ul}**                                                                                                        

  Drug                                                          *INH mono*               55            21(38.2)    1       1                  

  resistance                                                    *MDR-TB*                 53            31(58.5)    2.281   2.384   0.030^§^   1.089-5.220

                                                                *PDR -TB*                23            11(47.8)    1.484   1.627   0.348      0.588-4.496

  *katG*                                                        *wt*                     50            9(18.0)     1       1                  

                                                                *315Thr*                 74            54(73.0)    12.3    12.7    0.001^§^   6.357-14.80

                                                                *others*                 7             0(0)        \-      \-                 

  *inhA*                                                        *wt*                     103           59(57.3)    1       1                  

                                                                *-15T*                   28            4(14.3)     0.124   0.12    0.001^§^   0.038-0.375

  Beijing                                                       *No*                     26            4(15.4)     1       1                  

  genotype                                                      *Yes*                    105           59(56.2)    5.183   5.289   0.001^§^   1.832-15.26
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

NOTE. OR, odds ratio; 95%CI, confidence interval; wt, wild type; MDR-TB, multidrug-resistant tuberculosis; PDR-TB, polydrug-resistant tuberculosis.

\*: OR and 95%CI were adjusted by age, sex and county of subjects in binary logistic regression model.

§: *p*\< 0.05.

To further investigate the characteristics of *katG*315Thr mutant, the host and bacteriological variable were compared between the INH resistant isolates with the *katG*315Thr mutation group and those with other mutation/wild type group (Table [5](#T5){ref-type="table"}). The *katG*315Thr mutant isolates had a significantly higher proportion of MDR-TB (48.6%.vs.29.8%; *p*, 0.03), the relevant mutation in *rpoB*gene (47.3%.vs.24.6%, *p*, 0.008) compared to other mutation/wild type group. And meanwhile, this allele was more likely to be clustered (73.0%.vs.15.8%; *p*, 0.001) and belonged to the Beijing family (87.8%.vs. 70.2%; *p*, 0.012).

###### 

Comparison of host and bacteriological characteristics between isoniazid resistant isolates with katG315Thr mutations and other mutation/wild type

                                           No. of isolates with:                       
  ------------------------- -------------- ----------------------- ----------- ------- ---------
  Sputum smear              *Negative*     23(31.1)                26(45.6)    2.905   0.088
                            *Positive*     51(68.9)                31(54.4)            
  Treatment history         *New*          41(55.4)                39(68.4)    2.294   0.13
                            *Previously*   33(44.6)                18(31.6)            
  Cavity                    *No*           59(79.7)                52(91.2)    3.291   0.07
                            *Yes*          15(20.3)                5(8.8)              
  Drug resistance profile   *Others*       38(51.4)                40(70.2)    4.736   0.030\*
                            *MDR-TB*       36(48.6)                17(29.8)            
  *rpoB*mutation            *No*           39(52.7)                43(75.4)    7.11    0.008\*
                            *Yes*          35(47.3)                14 (24.6)           
  Clustered                 *No*           20(27.0)                48(84.2)    42.18   0.001\*
                            *Yes*          54(73.0)                9(15.8)             
  Beijing family            *No*           9(12.2)                 17(29.8)    6.314   0.012\*
                            *Yes*          65(87.8)                40(70.2)            

\*: *p*\< 0.05

Discussion
==========

This study attempted to gain further insight into the molecular basis of the INH resistant MTB circulating in the rural area of eastern China. Transmission of INH resistant MTB and its possible contribution to the epidemic of MDR-TB were also a concern. The majority of INH strains from TB dispensaries in the rural Chinese area, exhibited INH mono-resistance and the double-drug-resistance profile especially including extra resistance to RIF (53/131) and STR (37/131). These resistance profiles corroborated the pattern of acquisition of resistance to extra drug resistance especially for RIF and STR in INH resistant isolates \[[@B1]\].

The prevalence of the *katG*315Thr mutation in MTB strains around the world varies, especially with regard to the prevalence of TB. High TB burden regions \[[@B15]-[@B17]\] always observe a higher prevalence of the *katG*315Thr mutation in INH resistant strain compared to low TB burden areas \[[@B18]-[@B20]\]. The present study also demonstrated a high prevalence of the *katG*315Thr mutant allele in eastern rural China in around 50% of INH resistant isolates, which is consistent with the other report from China \[[@B21]\]. Furthermore in the current study, a significant correlation was confirmed between the common *katG*315Thr mutation in INH resistant strains and the presence of resistance to other drugs, especially for RIF. These observations might suggest that the INH resistant strain with the *katG*315Thr mutation may be more likely to develop the resistance to other 1^st^line drugs especially for RIF \[[@B22]-[@B24]\] than the strains with other forms of INH-resistance. Meanwhile, the high proportion of INH resistant *katG*315Thr mutant allele bore the mutation in *rpoB*gene, which was related to RIF resistance reported in China \[[@B25]\] and could be the reasons for the high risk of developing MDR in this allele.

The extensive transmission of the INH resistant MTB strain was observed in rural areas of eastern China, with 48.1% of the INH resistant MTB isolates in clusters. Most of INH resistant isolates with *katG*mutations were in clusters compared to wild type INH resistant isolates, suggesting its strong transmissibility, full virulence and survival advantage under the drug pressure in the host. This could be explained by the maintenance of the 30%\~40% catalase-peroxidase activity in the INH resistant strain with the *katG*315 Thr mutation \[[@B5],[@B6]\] compared to other mutations related to drug resistance. Consequently, this allele was suspected as the cause of some earlier reported outbreaks \[[@B26]-[@B28]\] of INH resistant TB in specific areas and populations. Furthermore, the current study observed that in a cluster containing strains with different drug resistance profile and resistance conferring mutations, the INH resistance was caused by this mutation. This increased the possibility that the INH resistant MTB strain with the *katG*315 mutation in the index person was more likely to experience a series of subsequent mutations, leading to the accumulation of extra drug resistance and the development of MDR- and/or extreme drug resistant(XDR)-TB \[[@B29]\]. The accumulation of drug resistance could be accredited by less efficiencies of standard chemotherapy, the subsequent mutation of drug resistance-related gene and selective survival of drug resistant strain during the recent transmission.

Apart from the role of the *katG*315Thr mutation, the transmissibility of INH resistant strain might be related to endemic characteristics of the Beijing family in rural China. The Beijing genotype is apparently the most prevalent genotype in China, representing of 80.2% INH resistant and 83% MDR-TB isolates in the current study. Our study also found that the MTB strain from the Beijing family was also the main source of recent transmission causing INH resistant TB. The Beijing genotype has been reported to be associated with treatment failure and relapse. Although the reasons for this are not known, it appears that the infections with the Beijing genotype strain may be more persistent, probably leading to longer duration of infectiousness and creating a better opportunity for transmission under the anti-TB drug pressure \[[@B30]\].

Additionally in the current study, INH resistant MTB was more likely to be clustered in smear-positive and previously diagnosed patients. The smear-positive status might extend the transmission period of the pathogen between hosts and allow MTB to attack more people in the surroundings of the index case. Although the previous TB could be cured by direct observed chemotherapy, those formerly treated cases could still be at risk for the TB re-infection from recent transmissions since the risk factors for TB (low socio-economic status, exposure to MTB etc.) are still present. In combination with these conditions, the risk of INH resistant MTB transmission between hosts increases.

The epidemic of MDR-TB can occur as a result of the spontaneous mutations in MTB and selection under suboptimal drug therapy or extensive transmission of the drug resistant MTB, or both combined. In the current study, a significant high proportion of MDR-TB isolates were observed in clusters compared to the other form of INH mono-resistant isolates. Most clusters with MDR-TB isolates also contained isolates with other drug resistance profiles including INH mono-resistance and poly drug-resistant tuberculosis simultaneously. Based on these observations, the epidemic of MDR-TB in rural China could be explained by two possibilities: 1) the epidemic of MDR-TB might result from the recent transmission of MDR-TB strains in an area ridden by INH resistant MTB. 2) Recent transmission of the drug resistant MTB and the selection of MTB under drug pressure might exert the symbiotic interaction in an epidemic of MDR-TB. The combination of INH resistance and maintained virulence might make it possible for some INH resistant strains, especially those with the *katG*315Thr mutation, to acquire extra drug resistance and become MDR-TB. It deserves further investigation to determine which mechanism may play the critical role in the epidemic of MDR-TB, since the implication behind it could be meaningful to evaluate the performance of local TB control as well as to determine the MDR-TB control strategies suitable for rural areas of China and as well as other similar high burden settings.

Conclusions
===========

INH resistant MTB was transmitted widely in eastern rural areas of China. Also the correlation of prevalence and transmission between INH resistant isolates especially with the *katG*315Thr mutation and MDR-TB was confirmed. Therefore, it is important to recognize the *katG*315Thr mutants among INH-resistant strains, which could be seen as a risk factor for subsequent development of MDR-TB. Early detection of the patients with INH resistant strains would facilitate the modification of treatment regimens and appropriate infection control measures can be taken in time to reduce the risk of further development and transmission of MDR-TB.
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